MedTrace Logo

Blood Transfusion Management in Patients With Mitral Valve Replacement in China

NCT03885570 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2019-09-19

No results posted yet for this study

Summary

The evaluation uses ΔHb as an independent factor combined with artificial intelligence (AI) to predict its impact on the prognosis and blood transfusion of patients undergoing cardiac surgery, thereby guiding perioperative clinical blood use and improving patient prognosis.

Conditions

  • Mitral Valve Replacement
  • Transfusion Reaction
  • Blood Transfusion Complication

Interventions

PROCEDURE

Mitral valve replacement

Blood transfusion

Sponsors & Collaborators

  • Second Xiangya Hospital of Central South University

    collaborator OTHER

  • Chinese Academy of Medical Sciences, Fuwai Hospital

    collaborator OTHER

  • The Affiliated Hospital Of Southwest Medical University

    collaborator OTHER

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • Zhejiang Provincial People's Hospital

    collaborator OTHER

  • Beijing Aerospace General Hospital

    collaborator OTHER

  • The Third Xiangya Hospital of Central South University

    lead OTHER

Principal Investigators

  • Rong Gui · The Third Xiangya Hospital of Central South University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-16
Primary Completion
2019-12-02
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03885570 on ClinicalTrials.gov